Grant Details
Grant Number: |
5R01CA071734-02 Interpret this number |
Primary Investigator: |
Rhoads, George |
Organization: |
Univ Of Med/Dent Nj-R W Johnson Med Sch |
Project Title: |
Psa Screening and Prostate Cancer Mortality |
Fiscal Year: |
1998 |
Abstract
DESCRIPTION: (Adapted from Applicant's Abstract). Prostate specific
antigen (PSA) screening to prevent death and disability from prostate cancer
has come into widespread use in the U.S. since 1989. The American Cancer
Society recommends that all men over age 50 have this blood test done
annually, and there is evidence that a majority of 50-79 year old men have
had the test at least once. While screening has led to a major increase in
the diagnosis of cancer and, consequently, i radical prostate surgeries, its
efficacy in preventing death from this disease is unproven. Prostate cancer
mortality has continued to increase. A population-based, case-control study
of PSA screening is proposed as the most timely approach to evaluate this
major screening modality. These studies have been used successfully to
evaluate other screening modalities and are predicated on the notion that if
screening prevents mortality, the decedents should be less likely to have
been screened than comparable men in the population. Cases will be 55-79
year old, married, New Jersey men, dying of prostate cancer in 1998-2000.
Married controls will be selected from random digit dialing (age 55-64) or
from Federal Medicare files (age 65-79) and will be matched to cases on age
and race. Case and control families will be interviewed to ascertain all
sources of medical care since 1989 and secure permission to review these
records for PSA screening. All inpatient and outpatient providers will be
contacted to ascertain instances of PSA screening since 1989. Analysis will
focus on whether or not cases were screened from 1989 to the time of
diagnosis. An exactly comparable calendar time period will be studied in
controls. The extent of protection (measured as an odds ratio for prostate
cancer death of less than 1.0) associated with screening will be calculated
before and after adjustment for potential confounders. This study is
proposed to provide the first direct estimate of the effectiveness of PSA
screening on prostate cancer mortality.
Publications
Statin use and fatal prostate cancer: a matched case-control study.
Authors: Marcella S.W.
, David A.
, Ohman-Strickland P.A.
, Carson J.
, Rhoads G.G.
.
Source: Cancer, 2012-08-15; 118(16), p. 4046-52.
EPub date: 2011-12-16.
PMID: 22180145
Related Citations